Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative
“Lumasiran was not genotoxic in an in vitro bacterial reverse mutation (Ames) assay, in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, or in vivo micronucleus assay in rats.”
Postmarketing requirement; later completed: 26-week Tg-rasH2 mouse and 2-year rat both negative
“Lumasiran was not carcinogenic in transgenic Tg-rasH2 mice following monthly subcutaneous administration of lumasiran for 26 weeks at doses of 150, 500, or 1500 mg/kg.”
Standalone monkey CV/respiratory telemetry (10, 100 mg/kg weekly x4), no effects; CNS in 8-week monkey study
“In a standalone cardiovascular safety pharmacology study in the monkey, the administration of lumasiran at 10 and 100 mg/kg weekly for a total of four doses had no immediate or delayed effects on clinical observations, qualitative or quantitative electrocardiogram parameters,”